Is THC a Vasodilator or Vasoconstrictor?

THC acts as both a vasodilator and a vasoconstrictor, and the answer depends almost entirely on which blood vessels you are talking about, what dose is involved, and how long the exposure lasts. In most peripheral vascular beds, the dominant acute response is vasodilation: blood vessels relax, blood flow to the skin and limbs increases, and blood pressure can drop. But in the brain and coronary arteries, THC has been linked to clinically significant vasoconstriction, sometimes with serious consequences. This dual identity makes THC unusual among recreational drugs and surprisingly difficult to pin down pharmacologically.

The Default Acute Response Is Peripheral Vasodilation

When researchers apply cannabinoids to isolated blood vessels or perfused vascular beds in a lab setting, the result in most cases is vasorelaxation, meaning the vessel walls loosen and the vessel opens wider. Vasoconstrictor responses also show up, but relaxation is the more common outcome across different tissue types and species.¹ In living humans, the most consistently observed cardiovascular effects of both marijuana smoking and intravenous THC are peripheral vasodilation and a faster heart rate. These show up as increased blood flow to the extremities, higher cardiac output, and variable changes in blood pressure.²

This peripheral vasodilation is what produces many of the familiar physical signs of being high. Your skin may feel warm or flushed. If you stand up quickly, you might feel lightheaded or dizzy, a sensation called orthostatic hypotension, which happens because your blood vessels are too relaxed to compensate for the sudden shift in gravity. That drop in vascular resistance is mediated partly through the autonomic nervous system and partly through cannabinoid receptors themselves.³ When THC is inhaled, it enters the bloodstream through the lungs and reaches peak blood levels within about six to ten minutes, so these vascular effects come on fast.⁴

Why the Blood Pressure Picture Is Not That Simple

If THC were a straightforward vasodilator, you would expect blood pressure to drop and stay down. Instead, what actually happens is more complicated. Animal studies dating back to the 1970s have documented that THC produces a biphasic blood pressure response: a brief rise in blood pressure followed by a sustained drop.⁵ The endocannabinoid anandamide, which shares some of THC’s receptor targets, can produce an even more complex triphasic pattern with three distinct pressure swings.⁶

In practical terms, this means that shortly after you smoke or vape cannabis, your heart rate climbs and your blood pressure may tick up slightly. Within minutes, the vasodilatory effect takes over and blood pressure starts falling, sometimes quite noticeably. Low doses of cannabinoids have been linked to a stronger sympathetic response, including faster heart rate, higher blood pressure, and elevated norepinephrine levels measured about 30 minutes after use. Meanwhile, a large observational study found no lasting association between cannabis use and hypertension over a 12-month follow-up.⁷ The research on cannabis and blood pressure is, as one group of investigators put it, contradictory. The direction of the effect depends on dose, route, tolerance, and timing.

One study in older adults using medical cannabis found that after three months, average 24-hour systolic blood pressure had dropped by about 5 mmHg and diastolic by about 4.5 mmHg, with the lowest point occurring around three hours after dosing.⁸ Those are modest but real reductions. Whether that translates into any clinical benefit for blood pressure management is a separate and still unanswered question, and no medical guidelines recommend cannabis for that purpose.

Red Eyes Are Vasodilation in Action

The most visible proof that THC dilates blood vessels is the classic “stoned” red eye. THC binds to cannabinoid receptors in the eye and causes the tiny blood vessels of the conjunctiva to widen. More blood flows through those vessels, and the white of the eye turns pink or red. Animal models have shown that this vasodilation is dose-dependent: the more THC, the redder the eyes.⁹

This same vasodilatory mechanism is tied to the well-known ability of THC to lower intraocular pressure, the fluid pressure inside the eye. Research in animal models suggests THC achieves this by activating CB1 and GPR18 receptors in the eye.⁹ This effect is why glaucoma patients were among the earliest advocates for medical cannabis. The pressure reduction is real, but it is temporary, lasting only a few hours, and the systemic side effects of THC make it a poor long-term glaucoma treatment compared to eye drops designed for the job. Interestingly, CBD may actually interfere with THC’s pressure-lowering effect in the eye, so full-spectrum cannabis products are not necessarily better for intraocular pressure than THC alone.

When THC Constricts Instead

Here is where the story turns more concerning. While THC tends to relax peripheral blood vessels, the opposite can happen in the brain and heart. Clinicians have documented cases of reversible cerebral vasoconstriction syndrome, or RCVS, in people who use marijuana. RCVS involves sudden narrowing of blood vessels in the brain, which can cause severe “thunderclap” headaches and, in some cases, stroke. One published case described a chronic daily marijuana user who developed recurrent watershed infarctions (small strokes in vulnerable areas between major arterial territories) with clear evidence of vasoconstriction in the anterior cerebral arteries. The vasoconstriction resolved with treatment and follow-up imaging confirmed the vessels had returned to normal, which is the hallmark of RCVS.¹⁰

A similar dynamic plays out in coronary arteries, the vessels that supply the heart itself. Cannabis use has been linked to coronary vasospasm, where a coronary artery suddenly clamps down and temporarily cuts off blood flow to part of the heart muscle. Case reports exist of left main coronary artery vasospasm triggered by cannabis, which is about as dangerous as coronary events get. Activation of CB1 receptors on vascular smooth muscle appears to be involved, and the resulting disruption of normal vasodilation, combined with oxidative stress, can promote endothelial dysfunction.¹¹

So THC simultaneously relaxes vessels in your arms and legs while potentially constricting vessels in the brain and heart. This paradox likely reflects the different receptor populations and signaling environments in different vascular beds. The same CB1 receptor activation that loosens a peripheral artery can trigger a different downstream cascade in a coronary artery, partly because of the local mix of other signaling molecules and the specific type of smooth muscle cells present. Researchers have identified a long list of possible mechanisms behind these vascular effects, including potassium and calcium channel activity, production of nitric oxide, release of the neuropeptide CGRP, and generation of reactive oxygen species.¹ The machinery is complex, and no single receptor pathway explains all of it.

How Dose, Tolerance, and Sex Affect the Response

The vascular effects of THC are not fixed. They shift depending on how much you use, how often, and who you are. A recent study presented at an American Heart Association meeting looked at the acute hemodynamic response to THC versus placebo and found that both male and female light users showed an increase in peak heart rate after a higher-potency THC exposure, but that frequent users did not show the same jump. Blood pressure, however, did not differ significantly between groups for systolic, diastolic, or mean arterial pressure.¹²

This finding matters because it suggests that tolerance builds to the heart rate effect but that the blood pressure response is already somewhat muted even in naive users under controlled conditions. Regular cannabis users often report that the initial cardiovascular “rush” fades over time, and the data supports that impression, at least for heart rate. What remains unclear is whether tolerance also dulls the vasodilatory or vasoconstrictive effects in specific vascular beds. Someone who no longer feels their heart pound after smoking might still be experiencing vasoconstriction in their coronary arteries without knowing it.

Synthetic cannabinoids deserve a separate warning here. These compounds, sometimes sold under brand names and sometimes labeled as “K2” or “Spice,” bind to CB1 receptors with roughly 100 to 200 times the potency of THC. Their cardiovascular effects are correspondingly more extreme, and reports of tachycardia and hypertension are common, particularly in young males.⁷ The vascular effects of plant-derived THC should not be conflated with those of synthetic cannabinoids, which represent a much higher-risk pharmacological profile.

Cannabis Arteritis

In rare cases, chronic cannabis use has been linked to a peripheral vascular disease called cannabis arteritis, first described in the medical literature in 1960. Cannabis arteritis closely resembles Buerger’s disease, a condition typically associated with tobacco smoking, and involves inflammation and narrowing of small and medium-sized arteries in the extremities.¹³ Both heavy and lighter cannabis users have developed it, though only a small number of people overall are affected, and the true prevalence is probably underestimated because the condition is not widely recognized.

Symptoms include cramping pain in the calves or feet during walking, Raynaud’s phenomenon (fingers or toes turning white or blue in the cold), loss of detectable pulses in the feet or hands, and in severe cases, tissue death or gangrene in the toes or fingers.¹⁴ Cannabis arteritis is, in a sense, the chronic vascular flip side of the acute vasodilation that THC is better known for. Over time, repeated exposure appears to damage the vessel lining in susceptible individuals, leading to progressive narrowing rather than relaxation. Cessation of cannabis use is the primary recommended treatment, and symptoms often improve or stabilize once use stops.

What Happens in the Uterine and Placental Circulation

One vascular bed where cannabis-related vasoconstriction has drawn increasing research attention is the uterine and placental circulation during pregnancy. A prospective study found that continued cannabis use during pregnancy was associated with increased resistance in the uterine arteries, as measured by higher pulsatility and resistance indices. Women who stopped using cannabis during pregnancy saw those indices decrease compared to controls. The uterine artery resistance in ongoing cannabis users was significantly higher than in women who used tobacco alone.¹⁵

A separate case-control study confirmed these findings using a different analytical approach. After adjusting for factors like maternal age and weight, cannabis use was a predictor for increased umbilical artery pulsatility, decreased cerebral-placental ratio, and increased uterine artery pulsatility at 33 to 35 weeks of gestation. Tobacco use also predicted increased umbilical artery resistance, but only cannabis predicted the full pattern of changes, including the decreased cerebral-placental ratio, which can indicate that the fetus is redirecting blood flow to the brain to compensate for reduced placental supply.¹⁶

These findings point to a vasoconstrictive or resistance-increasing effect of cannabis in the uterine vasculature, which runs counter to the peripheral vasodilation seen in other parts of the body. The practical implication is straightforward: cannabis use during pregnancy can reduce blood flow to the placenta and fetus, and this effect appears distinct from the effects of tobacco smoking alone.

The Receptor Puzzle

Part of the reason THC’s vascular behavior is so inconsistent across different tissues is that the underlying receptor pharmacology is genuinely complicated. THC primarily activates CB1 receptors, which are found on vascular smooth muscle cells, endothelial cells, nerve endings near blood vessels, and brain tissue. But activation of the same receptor in different tissue environments does not always trigger the same response. In coronary arteries, CB1 activation has been shown to promote endothelial dysfunction, generate reactive oxygen species, and release pro-atherogenic mediators, all of which can impair the vessel’s ability to relax and can promote long-term damage.¹¹

Meanwhile, in the eye and the peripheral vasculature, CB1 activation does the opposite, relaxing smooth muscle and increasing blood flow. Earlier research tested whether endothelium-dependent hyperpolarization, one way that vessels relax, was mediated by CB1 receptors. In guinea-pig carotid, rat mesenteric, and porcine coronary arteries, the endocannabinoid anandamide produced a hyperpolarization of smooth muscle cells that averaged about 12.6 millivolts in vessels with intact endothelium. But a synthetic CB1 agonist did not replicate the effect, suggesting this particular relaxation pathway is not actually running through CB1.¹⁷ The endocannabinoid system’s vascular effects involve multiple receptor types and second-messenger pathways, and isolating the exact contribution of each remains an active research problem.

This mechanistic uncertainty is worth keeping in mind when you hear simplified claims about cannabis and cardiovascular health, whether from advocates or critics. THC is not simply a vasodilator that relaxes you and lowers your blood pressure. It is also not simply a dangerous vasoconstrictor that puts your heart and brain at risk. It is a compound that does different things in different tissues, at different doses, and in different people, and the research community is still mapping out those differences with anything approaching completeness.

Temperature, Skin, and the Peripheral Flush

One of the less discussed consequences of THC-induced peripheral vasodilation is its effect on body temperature. When blood vessels near the skin dilate, more warm blood flows to the body’s surface, which means heat dissipates faster. In animal studies, THC at human-relevant doses showed a tendency to decrease brain and muscle temperatures, though outright hypothermia only occurred at the highest doses tested. At that high dose, the temperature drop in the brain was larger than in muscle tissue, suggesting the cooling was partly driven by reduced metabolic activity in the brain rather than peripheral heat loss alone.¹⁸

For most people using cannabis in a comfortable indoor environment, this temperature effect is negligible or unnoticed. But in cold outdoor settings, the combination of peripheral vasodilation and reduced metabolic drive could theoretically accelerate heat loss. This is not a well-studied scenario in humans, and the risk is speculative, but it follows directly from the same vasodilation that gives you red eyes and warm hands. The flush you feel is your body giving up heat more efficiently, whether you want it to or not.

1
PubMed Central. Vascular targets for cannabinoids: animal and human studies
2
ScienceDirect. Endocannabinoids and Vascular Function
3
PubMed. Cardiovascular consequences of marijuana use
4
PubMed Central. Mechanisms of Action and Pharmacokinetics of Cannabis
5
PubMed Central. A Systematic Review and Meta-Analysis of the In Vivo Haemodynamic Effects of Δ9-Tetrahydrocannabinol
6
PubMed Central. Triphasic blood pressure responses to cannabinoids: do we understand the mechanism?
7
PubMed Central. Hypertensive Crisis-Related Hospitalizations and Subsequent Major Adverse Cardiac Events in Young Adults with Cannabis Use Disorder: A Nationwide Analysis
8
ScienceDirect. Cannabis is associated with blood pressure reduction in older adults – A 24-hours ambulatory blood pressure monitoring study
9
PubMed Central. Adverse Ocular Impact and Emerging Therapeutic Potential of Cannabis and Cannabinoids: A Narrative Review
10
PubMed Central. Marijuana-related Reversible Cerebral Vasoconstriction Syndrome
11
Cardiovascular Revascularization Medicine: Interesting Cases. A Rare Case of Cannabis-Induced Left Main Coronary Artery Vasospasm: A Case Report and Review of Literature
12
Circulation. Abstract 4341683: Sex Differences in Acute Hemodynamic Response to Delta-9-Tetrahydrocannabinol Compared to Placebo: Impact of Cannabis Use Frequency
13
PubMed Central. Cannabis arteritis
14
PubMed Central. Cannabis arteritis: A case report and brief review of the literature
15
Early Human Development. A prospective study on intrauterine cannabis exposure and fetal blood flow
16
PubMed Central. Intrauterine cannabis exposure and fetal and maternal blood flow: a case–control study
17
British Journal of Pharmacology. Cannabinoid CB1 receptor and endothelium-dependent hyperpolarization in guinea-pig carotid, rat mesenteric and porcine coronary arteries
18
PubMed Central. Behavioral and temperature effects of delta 9-tetrahydrocannabinol in human-relevant doses in rats